Immunosuppression

News

Related Video News

No related video news stories found.

Organic Broadcast Project

Related Videos

No related videos found.

StemCells, Inc. Announces First Human Neural Stem Cell Transplant in Landmark Myelination Disorder Trial

Published February 10, 2010, 6:00 am, GlobeNewswire via Yahoo! Finance

PALO ALTO, Calif. -- StemCells, Inc. announced today that its proprietary HuCNS-SC® human neural stem cells have been used to treat the first patient enrolled in its Phase I clinical trial in Pelizaeus-Merzbacher Disease , a myelination disorder that afflicts male children. The stem cells were administered yesterday at the University of California, San Francisco Children's Hospital by direct ...

Discover News | Full Story


Athersys Receives U.S. Patent Covering Adult Stem Cell Composition & Production

Published February 10, 2010, 3:30 am, GlobeNewswire via Yahoo! Finance

CLEVELAND -- Athersys, Inc. announced today that it has been granted U.S. patent 7,659,118 that covers non-embryonic multipotent stem cells, their isolation and expansion, and related pharmaceutical compositions. Athersys also announced that it has been granted – and the opposition period has cleared – EP patent EP1218489B1 that covers non-embryonic pluripotent stem cells, their isolation ...

Discover News | Full Story


Lux Biosciences Files For LUVENIQ™ Approval In US And Europe For Noninfectious Uveitis

Published February 6, 2010, 12:48 am, Medical News Today

Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye. Efficacy of LX211 in ...

Discover News | Full Story


Lux Biosciences seeks US and European marketing approval for LUVENIQ

Published February 4, 2010, 9:16 pm, News-Medical-Net

Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

Discover News | Full Story



News Directory

Get started fast by using a pre-defined news directory category

Breaking News
and Top Stories
Business
Earnings, Economy, Personal Finance, and Stock Markets
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss
Politics
Congress, Supreme Court, and White House
Science
Animals, Astronomy, Biotechnology, Space, and Weather
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis
Technology
Communications, Hardware, Internet, Personal Technology, and Software
United States
and Crimes and Trials
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East


© Copyright 2005-2006 News Meme, All Rights Reserved | More News | Link Index | OSWD Design

Powered by Odin Assemble 2.5a